

Antiplatelet Effect of Single Antiplatelet Therapy With Prasugrel and Oral Anticoagulation After Stent Implantation in a Rabbit Arteriovenous Shunt Model

Sho Torii, MD, PhD; Tadashi Yamamoto, MD, PhD; Norihito Nakamura, MD;
Takeshi Ijichi, MD, PhD; Ayako Yoshikawa; Yusuke Ito, PhD;
Atsuhiko Sugidachi, PhD; Yuji Ikari, MD; Gaku Nakazawa, MD, PhD

The authors apologize for the written mistakes in the Result sections. Corrections are shown below.

1) From Page 507, Line 21 to Page 508, Line 2

Incorrect:

The volume of the thrombus (amount of protein) around stent struts was lowest in the Triple group, followed by the Prasugrel+OAC and conventional DAPT groups, and was highest in the Control group (median [IQR] 0.49 [0.38–1.11], 0.74 [0.46–1.34], 0.96 [0.50–1.41], 2.92 [2.14–4.24], and **3.72** [2.30–5.15] mg/mL in the Triple, Prasugrel+OAC, Conventional DAPT, Aspirin+OAC, and Control groups, respectively; **Figure 4; Table 1**).

Correct:

The volume of the thrombus (amount of protein) around stent struts was lowest in the Triple group, followed by the Prasugrel+OAC and conventional DAPT groups, and was highest in the Control group (median [IQR] 0.49 [0.38–1.11], 0.74 [0.46–1.34], 0.96 [0.50–1.41], 2.92 [2.14–4.24], and **3.73** [2.30–5.15] mg/mL in the Triple, Prasugrel+OAC, Conventional DAPT, Aspirin+OAC, and Control groups, respectively; **Figure 4; Table 1**).

2) Page 508, Table 1

Group 1 vs. Group 2	Thrombus volume: Group 1 vs. Group 2 (mg/mL)	P value
Control vs. Triple	3.73 vs. 0.49	0.003
Control vs. Prasugrel+OAC	3.73 vs. 0.74	0.005
Control vs. DAPT	3.73 vs. 0.96	0.007
Control vs. Aspirin+OAC	3.73 vs. 2.92	0.9
Triple vs. Prasugrel+OAC	0.49 vs. 0.74	0.99
Triple vs. DAPT	0.49 vs. 0.96	0.99
Triple vs. Aspirin+OAC	0.49 vs. 2.92	0.02
Prasugrel+OAC vs. DAPT	0.74 vs. 0.96	0.99
Prasugrel+OAC vs. Aspirin+OAC	0.74 vs. 2.92	0.03
DAPT vs. Aspirin+OAC	0.96 vs. 2.92	0.04

DAPT, dual antiplatelet therapy; OAC, oral anticoagulant; Triple, treatment with prasugrel, aspirin, and warfarin.

Original article: *Circ Rep* 2021; 3: 504–510 doi:10.1253/circrep.CR-21-0084

Mailing address: Gaku Nakazawa, MD, PhD, Department of Cardiology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-Sayama 589-8511, Japan. E-mail: gnakazawa@med.kindai.ac.jp

All rights are reserved to the Japanese Circulation Society. For permissions, please e-mail: cr@j-circ.or.jp

ISSN-2434-0790



3) Page 508, Table 2

Table 2. Difference in Bleeding Time		
Group 1 vs. Group 2	Bleeding time: Group 1 vs. Group 2 (s)	P value
Control vs. Triple	210 vs. 900	0.08
Control vs. Prasugrel+OAC	210 vs. 345	0.99
Control vs. DAPT	210 vs. 270	0.99
Control vs. Aspirin+OAC	210 vs. 405	0.99
Triple vs. Prasugrel+OAC	900 vs. 345	0.1
Triple vs. DAPT	900 vs. 270	0.04
Triple vs. Aspirin+OAC	900 vs. 405	0.2
Prasugrel+OAC vs. DAPT	345 vs. 270	0.99
Prasugrel+OAC vs. Aspirin+OAC	345 vs. 405	0.99
DAPT vs. Aspirin+OAC	270 vs. 405	0.9

DAPT, dual antiplatelet therapy; OAC, oral anticoagulant; Triple, treatment with prasugrel, aspirin, and warfarin.